HIV, Flu & HBV/HCV Focus of Antiviral Drug Discovery Conference on March 15-16, 2000, in New Jersey

Princeton, New Jersey (PROTEXT) - Pharmaceutical industryadvances in the discovery and development of novel antiviralagents in HIV, influenza/respiratory, and hepatitis B & C, willbe presented in depth on March 15-16, 2000 at the Hyatt RegencyHotel in Princeton, NJ, announces Strategic Research Institute. The conference will feature work in the neuraminidaseinhibitor area presented by Roche (Tamiflu), Glaxo Wellcome(Relenza), and RW Johnson PRI (RWJ-270201), Agouron's proteaseinhibitor for rhinovirus infection, and clinical summary ofViroPharma's Pleconaril, a novel therapy for picornaviraldisease. In HIV, the conferences focuses on Trimeris' fusion inhibitor,T-20 and Merck's Integrase inhibitor; also featured will bereverse transcriptase inhibitors, plus contributions from othercompanies. The HBV/HCV section will feature discussion of ScheringPlough's Ribavirin, Roche's Pegainterferon alfa-2a andcontributions from Eli Lilly and Glaxo Wellcome; Emory Universityand Novirio Pharmaceuticals will present new data on nucleosideanalogs and L-nucleosides, both having shown potent activityagainst hepatitis B. To request the agenda and/or register, please contact CamilleCoward of Strategic Research at ccoward@srinstitute.com or byphone at 212-967-0095, ext 255. ots Original Text Service:Strategic Research Institute Internet: http://www.newsaktuell.deContact: Camille Coward of Strategic Research,ccoward@srinstitute.com, (USA) 212-967-0095, ext 255 Web site:http://www.srinstitute.com

Subscribers please note that material bearing the slug"PROTEXT" is not part of CTK's news service and is not to bepublished under the "CTK" slug. Protext is a commercial serviceproviding distribution of press releases from clients, who areidentified in the text of Protext reports and who bear fullresponsibility for their contents.

PROTEXT